TAK-165 can inhibit HT1376, UMUC3, T24 (bladder), ACHN (kidney), DU145, LNCaP, LN-REC4 (prostate) cell lines, which are observed HER2 expression, with IC50 from 0.09 to greater than 25 micromol/L. The prostate cancer cell lines are all sensitive to mubritinib (TAK 165).Mubritinib (TAK 165) can inhibit prostate cancer cell lines with IC50 from 0.053to 4.62 micromol/L.